Please login first
Indeno[1,2-b]indol Inhibitors of Human Protein Kinase CK2 and Their Impact on Different Tumor Cell Lines
* 1 , 2 , 3
1  Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, PharmaCampus, Corrensstraße 48, 48149 Münster, Germany
2  ISPB-Faculté de Pharmacie, Université Claude Bernard Lyon 1, EA 4446 Bioactive Molecules and Medicinal Chemistry, 8 avenue Rockefeller, 69373 Lyon cedex 08, France
3  Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Pharma Campus, Corrensstraße 48, 48149 Münster, Germany

Published: 01 November 2016 by MDPI in 2nd International Electronic Conference on Medicinal Chemistry session ECMC-2
Abstract:

Increased protein kinase CK2 activity is involved in many human diseases such as cancer (1). In consequence CK2 is an emerging major target for drug design. Several indeno[1,2-b]indole-9,10-dione derivatives containing N5-isopropyl substitutions on the C-Ring were synthesized and have been reported as potent ATP-competitive CK2 inhibitors (2,3).

Here we report on the evaluation of these inhibitors, containing different substituents in the A- and D-rings, for their effects on various tumor cell lines: breast cancer cells MCF-7, lung carcinoma cells A427 and epidermal cancer cell line A431.

The most potent CK2 inhibitor contains an O-prenyl residue R1 and exhibits an IC50 value of 0,025 µM. Treatment of MCF-7 cells with 20 µM of that compound for 24 h results in a reduction of the total cell number by 90%. Most of the remaining cells exhibited apoptotic morphology and showed nearly none proliferating activity. In contrast treatment of A431 cells and A427 cells caused only a moderate decrease of cell proliferation by 30% for all tested compounds.

This study shows that potent CK2 inhibitors as tested can exhibit distinct effects on different tumor cell lines. Compound containing an O-prenyl residue R1 appears to be an antiproliferating agent with high activity toward MCF7 cells.

 References

  1. Guisiano, S. et al: Eur. J. Cancer 2011, 47, 792-801
  2. Alchab, F. et al : Pharmaceuticals 2015, 8, 279-302
  3. Gozzi, et al: J. Med. Chem 2015, 58, 265-277
Keywords: CK2, CK2 inhibitors, Indeno[1,2-b]indole-9,10-dione, MCF-7 cells
Top